IDO1 is an Integral Mediator of Inflammatory Neovascularization
Tài liệu tham khảo
Blaschitz, 2011, Vascular endothelial expression of indoleamine 2,3-dioxygenase 1 forms a positive gradient towards the feto-maternal interface, PLoS One, 6, e21774, 10.1371/journal.pone.0021774
Cao, 2011, Forty-year journey of angiogenesis translational research, Sci. Transl. Med., 3, 114rv3, 10.1126/scitranslmed.3003149
Connor, 2009, Quantification of oxygen-induced retinopathy in the mouse: a model of vessel loss, vessel regrowth and pathological angiogenesis, Nat. Protoc., 4, 1565, 10.1038/nprot.2009.187
Dinatale, 2010, Kynurenic acid is a potent endogenous aryl hydrocarbon receptor ligand that synergistically induces interleukin-6 in the presence of inflammatory signaling, Toxicol. Sci., 115, 89, 10.1093/toxsci/kfq024
Hou, 2007, Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses, Cancer Res., 67, 792, 10.1158/0008-5472.CAN-06-2925
Ibe, 2001, Tumor rejection by disturbing tumor stroma cell interactions, J. Exp. Med., 194, 1549, 10.1084/jem.194.11.1549
Lee, 2013, Ethyl pyruvate inhibits retinal pathogenic neovascularization by downregulating HMGB1 expression, J. Diabetes Res., 2013, 245271, 10.1155/2013/245271
Liu, 2010, Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity, Blood, 115, 3520, 10.1182/blood-2009-09-246124
Liu, 2014, GCN2-dependent metabolic stress is essential for endotoxemic cytokine induction and pathology, Mol. Cell. Biol., 34, 428, 10.1128/MCB.00946-13
Metz, 2014, IDO2 is critical for IDO1-mediated T-cell regulation and exerts a non-redundant function in inflammation, Int. Immunol., 26, 357, 10.1093/intimm/dxt073
Middleton, 2014, Interleukin-6: an angiogenic target in solid tumours, Crit. Rev. Oncol. Hematol., 89, 129, 10.1016/j.critrevonc.2013.08.004
Muller, 2005, Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy, Nat. Med., 11, 312, 10.1038/nm1196
Muller, 2008, Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase, Proc. Natl. Acad. Sci. U. S. A., 105, 17073, 10.1073/pnas.0806173105
Muller, 2010, Immunotherapeutic suppression of indoleamine 2,3-dioxygenase and tumor growth with ethyl pyruvate, Cancer Res., 70, 1845, 10.1158/0008-5472.CAN-09-3613
Munn, 1999, Inhibition of T cell proliferation by macrophage tryptophan catabolism, J. Exp. Med., 189, 1363, 10.1084/jem.189.9.1363
Munn, 2004, Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes, J. Clin. Invest., 114, 280, 10.1172/JCI200421583
Palmer, 2012, A novel angiopoietin-derived peptide displays anti-angiogenic activity and inhibits tumour-induced and retinal neovascularization, Br. J. Pharmacol., 165, 1891, 10.1111/j.1476-5381.2011.01677.x
PEEK, 2005, Inflammation in the genesis and perpetuation of cancer: summary and recommendations from a national cancer institute-sponsored meeting, Cancer Res., 65, 8583, 10.1158/0008-5472.CAN-05-1777
Qin, 2000, CD4+ T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells, Immunity, 12, 677, 10.1016/S1074-7613(00)80218-6
Smith, 2012, IDO is a nodal pathogenic driver of lung cancer and metastasis development, Cancer Discov., 2, 722, 10.1158/2159-8290.CD-12-0014
Stahl, 2012, SOCS3 is an endogenous inhibitor of pathologic angiogenesis, Blood, 120, 2925, 10.1182/blood-2012-04-422527
Taylor, 1991, Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism, FASEB J., 5, 2516, 10.1096/fasebj.5.11.1907934